Recombinant AAV Production via Modular Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated virus (rAAV) are laborious and impractical for high-throughput screening, especially for targeting non-dividing cells like neuronal cells, and there is a need for a simple and effective method to prepare and test rAAV for gene therapy applications.
Innovation Solution
The development of methods for preparing rAAV using a recombinant construct packaged in an adeno-associated viral vector (AAV), which includes infecting cells with AAV containing exogenous DNA and providing helper functions to facilitate replication and packaging, allowing for the production and testing of rAAV for efficient gene editing in eukaryotic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional methods for producing recombinant adeno-associated virus (rAAV) are used, then the production process is laborious and impractical for high-throughput screening, but the current method lacks simplicity and scalability
Solution Approach 1:
The patent segments the rAAV production process into distinct modular components: (1) transfection of packaging plasmids into HEK293 cells, (2) infection with AAV containing exogenous DNA, (3) provision of helper functions, and (4) harvest of supernatant. This segmentation enables parallel processing and high-throughput screening while maintaining simplicity through standardized protocols for each module.
Solution Approach 2:
The patent uses HEK293 cells as an intermediary system that facilitates the production of rAAV. These cells serve as a platform that receives multiple plasmids and AAV inputs, processes them through controlled infection and replication, and outputs standardized rAAV-containing supernatant. This intermediary approach simplifies the overall manufacturing process while enabling scalable production.
2Adaptability or versatility
If current rAAV production methods are used, then the process is not suitable for targeting non-dividing cells like neuronal cells, but the invention enables effective targeting of such cells
Solution Approach 1:
The patent modifies key parameters of the rAAV production process, including the use of specific AAV serotypes with enhanced tropism for non-dividing cells, optimization of helper function provision, and adjustment of infection conditions. These parameter changes enable the system to effectively target neuronal and other non-dividing cells while maintaining high productivity through the standardized supernatant harvest method.
3Reliability
If traditional rAAV production and testing methods are used, then the process is laborious and not reproducible, but the invention provides readily accessible and reproducible rAAV aliquots
Solution Approach 1:
The patent performs preliminary actions by pre-packaging the exogenous DNA into AAV particles under controlled conditions, then storing these as standardized stocks. This preliminary preparation allows for reproducible aliquoting and distribution of rAAV without requiring complex production and testing procedures at each use point, thereby enhancing reliability while reducing operational complexity.
Solution Approach 2:
The patent creates standardized copies of rAAV containing specific exogenous DNA through repeated use of the same packaging plasmids and infection protocols. This copying approach ensures that each batch of rAAV is reproducible and can be reliably tested and stored, simplifying the overall process while maintaining high reliability across multiple experiments and applications.
Data Source
AI summary
The present invention generally relates to methods and compositions used delivery of gene editing compositions including transcriptional effectors with parvovirus and preferred methods for making same.